Failure of omalizumab for treatment of severe adult atopic dermatitis

Failure of omalizumab for treatment of severe adult atopic dermatitis

Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab to improve atopic dermatitis in 3 patients when administered for 4 months.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Academy of Dermatology 2005-08, Vol.53 (2), p.338-340
Hauptverfasser: Krathen, Richard A., Hsu, Sylvia
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Age Factors
Allergic diseases
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Biological and medical sciences
Dermatitis, Atopic - drug therapy
Dermatology
Female
Humans
Immunopathology
Male
Medical sciences
Middle Aged
Omalizumab
Severity of Illness Index
Skin allergic diseases. Stinging insect allergies
Treatment Failure
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Atopic dermatitis has been associated with elevated levels of IgE. Omalizumab is a monoclonal anti-IgE antibody currently approved for the treatment of asthma. We report the failure of omalizumab to improve atopic dermatitis in 3 patients when administered for 4 months.
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2005.02.014